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Background: Tuberculosis (TB) presents a serious problem in Mozambique. HIV prevalence among TB patients is
estimated at 47%. A delay in having their first CD4+ cell count could lead to a missed opportunity for ART initiation
due to a CD4+ cell increase above the cut-off caused by TB treatment. The objective is to describe CD4+ cell
response during TB treatment and quantify the effect of TB treatment and ART on this response.
Methods: All new HIV + adult TB cases in 2007 from three TB clinics in Mozambique were included. Data on TB
diagnosis and treatment and HIV parameters were collected. A general mixed model was used for CD4+ cell count
response.
Results: 338 HIV + patients were notified and 252 (75%) were included in the analysis. Using TB medication was not
independently associated with the CD4+ count response (19 cells/mm3; 95% CI: -40 to 79; p = 0.529). ART-use was
associated with statistically significantly higher CD4+ cells compared to no ART-use (81 cells/mm3; 95% confidence
interval (CI): 12 to 151; p = 0.022).
Conclusion: In this study, no independent effect of TB treatment on CD4+ cell count was found. HIV-infected TB
patients on ART had a significantly higher CD4+ cell count than those not receiving ART. CD4+ cell counts for
patients not on ART at TB treatment start, remained below the cut off for initiating ART during the first three
months of TB treatment; therefore some delay in getting the first CD4+ cell count would not lead to missing the
opportunity to start ART.Background
Tuberculosis (TB) presents a serious problem in
Mozambique with case notifications rising dramatically
since the start of this century. The World Health
Organization (WHO) estimated the incidence of all
forms of TB in Mozambique in Mozambique at the time
of the study (2007) at 431 per 100.000 population [1].
The increase in TB notifications is partly driven by the
Human Immunodeficiency Virus (HIV) epidemic [2].
The national HIV prevalence is estimated at 15%, based
on antenatal sentinel surveillance among pregnant
women 15 to 49 years of age [3]. WHO estimated the
HIV prevalence in adult TB cases at 47% in 2007 [1].* Correspondence: brouwer.miranda@gmail.com
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reproduction in any medium, provided the orIn Sub Saharan Africa, people unaware of their HIV-
infection present often to the health care services with
TB as the first AIDS defining illness. Several studies
found that TB clinics are well positioned to identify new
HIV-infected individuals and to provide access to HIV
services [4,5].
Following international recommendations, Mozambique
started implementing TB-HIV collaborative activities
in 2006 [6]. TB treatment staff provide HIV counsel-
ling and testing, and offer co-trimoxazole preventive
therapy (CPT) at the TB clinic to HIV-infected TB
patients. They refer co-infected patients to HIV ser-
vices for further care and treatment, including anti-
retroviral therapy (ART). According to the 2006
national guidelines, the timing of ART initiation in
relation to TB treatment depends on the level of im-
munosuppression [7]. Patients with a CD4+ cell count
less than 200 cells/mm3, should start ART as soon asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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200 and 350 cells/mm3 ART is delayed until the first
two months of TB treatment are completed. At the end
of 2009, WHO published new recommendations to start
ART as soon as possible in TB-HIV co-infected patients
regardless of their immunosuppression [8]. At the same
time, the Ministry of Health in Mozambique published
new HIV treatment guidelines that had not yet incorpo-
rated the new WHO recommendations [9]. These new
Mozambican guidelines are still valid presently and the
start of ART in co-infected patients still depends on
the level of immunosuppression, though the lower level
is of the CD4+ cell count is 250 cells/mm3 compared
to 200 cells/mm3 in the 2006 guidelines.
Several studies described an increase in CD4+ cell count
during TB treatment for non-immune compromised TB
patients [10,11]. CD4+ cell response during TB treatment
in HIV-infected TB patients is less clear and only a few
studies addressed this question. One South African study
showed a significant increase of CD4+ cell count after
3 month of TB treatment. Another South African study of
HIV-infected TB patients did find an increase in CD4+
cell count during TB treatment, though this was not sta-
tistically significant [12]. In both these studies, ART was
not available to the participants.
In Mozambique, not all health facilities delivering HIV
services have equipment for the assessment of CD4+
cells. Therefore, newly diagnosed HIV-infected TB
patients may experience a delay in having their first
CD4+ cell count result available. Should the CD4+ cell
count during TB treatment increase in the HIV-
infected TB patients as in non-immune compromised
TB patients, the CD4+ cell count might become higher
than the cut-off value for initiating ART. An opportun-
ity for start of ART would be missed.
The objective of this study was to describe the CD4+
cell count response during TB treatment and to quantify
the effect of TB treatment and ART on the CD4+ cell
count response. Through the CD4+ cell count response
we assessed whether a risk exists for missing an opportun-
ity to start ART in the routine setting of Mozambique due
to late CD4+ cell count availability in HIV-infected TB
patients, and the prioritization of ART for TB-HIV co-
infected patients with the lowest CD4+ cell counts.Methods
Ethics statement
The National Bio-ethic Committee of the Ministry of
Health of Mozambique and the Institutional Review
Board of the University of Washington in Seattle, USA,
approved the study protocol. Both ethics committees
approved that informed consent was not obtained as the
study was based on routinely collected data.Study design and setting
We performed a retrospective observational study in
three purposely-selected health facilities in Manica prov-
ince, Mozambique. Selection criteria were the presence
of both TB and HIV treatment services in the same facil-
ity and at least 150 TB patients notified in 2007. One fa-
cility was an urban health centre in the provincial
capital; the other two were rural health facilities about
20 and 90 kilometres from the provincial capital. Within
these clinics, we collected the information on HIV dis-
ease parameters of all new notified TB patients of
16 years and older with a positive HIV test recorded in
the TB register from January to December 2007.
In Mozambique, smear microscopy is the main TB
diagnostic. In the participating facilities, diagnosis of
sputum smear-negative and extrapulmonary TB occurs
mainly on clinical assessment and hardly ever on radi-
ology. All new adult TB patients receive a standard
course of TB treatment consisting of two months isonia-
zid, rifampicin, ethambutol and pyrazinamide followed
by 4 months isoniazid and rifampicin. The standard first
line ART regimen consists of two nucleoside reverse-
transcriptase inhibitors, lamivudine and stavudine, with
either the non-nucleoside reverse transcriptase inhibitor
(NNRTI) nevirapine or efavirenz. The national guide-
lines recommend switching from neviripine to efavirenz
in patients that receive a rifampicin containing treat-
ment regimen [7].Data collection
The facility’s TB supervisor collected the data of the
2007 cohort using standard data collection forms in July
and August 2009. Data collected from the TB register
included: age, sex, type and category of TB, treatment
regimen, start date of TB treatment, initial smear exam-
ination result, HIV test result and TB treatment out-
come. If the treatment outcome was death, its date was
recorded.
We identified the HIV record of the HIV-positive TB
cases through the unique HIV patient number if
recorded in the TB register. In addition, local staff famil-
iar with the patients identified some HIV patient
records. If these methods did not lead to identification
of the patient record, we searched the electronic HIV-
database using the patient’s name and age taken from
the TB register. If the data matched, we took the unique
HIV patient number from the electronic database and
used it to locate the HIV patient record. We limited the
identification of the HIV patient record to those HIV-
positive TB patients registered with the HIV services in
the same health facility.
We collected available CD4+ cell count results in the
6 months TB treatment period, the date of these results,
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HIV patient record.Statistical analysis
We entered the data in EpiData version 3.1 and performed
descriptive analysis with EpiData Analysis V2.2.1.171. We
used STATA version 11 (StataCorp, College Station,
Texas, USA) for analysis of the CD4+ cell counts.
We modelled the evolution of the CD4+ cell count
during TB treatment using a mixed effect model. This
model deals adequately with repeated measurements of
the outcome variable [13]. The model incorporates esti-
mated values for missing data based on all other avail-
able data. With this model we used optimally all
available CD4+ cell counts including all patients with at
least one CD4+ cell count in the model, regardless of
the number of missing values these patients have. We
used a random intercept model with an independent co-
variance structure for estimation of the CD4+ cell count
over time. We compared the mean CD4+ cell count for
the time updated variables of TB treatment use and
ART use. In addition we included age and sex in the
model as potential confounding variables. The model
used the absolute CD4+ cell count values to estimate the
effect of TB treatment and ART on CD4+ cell response.
We assumed that once a patient starts ART, the patientTable 1 Demographical and clinical characteristics for HIV-po






Median (IQR†) age in years 32 (26–39)
Type of TB
Smear-positive Pulmonary TB 156 (62%)
Smear-negative Pulmonary TB 79 (31%)
Extra Pulmonary TB 17 (7%)
TB Treatment outcome




no ART during the study period 67 (27%)
started ART before TB diagnosis 81 (32%)
started ART during TB treatment 86 (34%)
started ART after TB treatment 18 (7%)
* One patient did not have the sex recorded in the TB register.
† IQR = Inter Quartile Range.
& N/A =Not applicable.continues ART until the end of the observation period.
We did not adjust for the type of NNRTI because there
is no evidence that there is a differential CD4+ count in-
crease when comparing a nevirapine-based or efavirenz-
based regimen [14].Definitions
We defined the baseline CD4+ cell count at the start of
TB treatment as the CD4+ count closest to the start of
TB treatment within a window of 12 weeks before until
2 weeks after the start of TB treatment. We allocated all
other CD4+ cell counts to a single fixed time-point with
a window ranging from 2 to 6 weeks. If multiple CD4+
cell counts were available for a specific time-point, we
included the one closest to the midpoint of the time
window in the analysis.
To determine whether the CD4+ cell count was
obtained while using TB treatment, we used WHO stand-
ard treatment outcomes to define the end of TB treatment
[15]. The end of TB treatment for treatment ‘success’
(cured or treatment completed) was 180 days after start of
TB treatment. For ‘failure’ (smear positive after five
months for sputum smear positive cases), the end of treat-
ment was 150 days (5 months) after start. For ‘default’
(interrupted treatment for two or more consecutive
months), ‘transfer out’ (transferred to another TB unit withsitive new TB patients
s Not registered at HIV




45 (55%) 152 (46%)
37 (45%) 181 (54%)
33 (24.8-40.3) 32 (26–39.3)
49 (60%) 205 (61%)
28 (34%) 107 (32%)
5 (6%) 22 (7%)
63 (77%) 259 (78%)
17 (21%) 69 (21%)
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TB treatment was 90 days after the start date. For patients
who died, TB treatment ended at the date of death or
90 days after start of TB treatment if unknown.
Results
From January 1st until December 31st 2007, 591 new
TB patients were notified. Of these, 478 (81%) were
tested for HIV and 338 (71%) had a positive test. Of
these, 274 (81%) were registered with the HIV services
in the same facility. HIV patient records were identified
for 256 (93%) patients. Four patients were excluded from
the analysis due to an identification mismatch, leaving
252 patients for analysis. All patients started TB treat-
ment. Patient characteristics and the ART status are
given in Table 1.
Of the 252 patients available for analysis, 25 (10%) had
not a single CD4+ count recorded and 16 (6%) had only
CD4+ counts before the period defined as the start of
TB treatment. For the remaining 211 (84%) patients, a
total of 271 CD4+ counts were available at the start of
or during TB treatment. Figure 1 shows the number of
available CD4+ cell counts at each time-point.
A baseline CD4+ cell count was available for 149
patients with 48 (32%) and 23 (15%) taken while the pa-
tient received TB treatment or ART respectively. Of the
122 CD4+ count results after the start of TB treatment,
81(66%) were obtained while the patient was on ART.
Over the full observation period of 6 months, using
TB treatment was not statistically significant associated
with the CD4+ cell count response. Patients using TB
treatment had a CD4+ cell increase of 19 cells/mm3
(95% CI: -50 to 79; p = 0.529) compared to patients not
receiving TB treatment. ART use was statistically signifi-
cantly associated with CD4+ cell response during the
observation period. Patients using ART had a CD4+ cellFigure 1 Estimated CD4+ cell counts by ART use. Legend: The
numbers below the figure show the CD4+ cell counts available per
time-point.increase of 81 cells (95% CI: 12 to 151; p = 0.222) com-
pared to patients not using ART.
The CD4+ cell count response during TB treatment by
ART status is shown in Figure 1.
Discussion
In this study, TB treatment in TB-HIV co-infected
patients had no significant effect on CD4+ cell count.
The evolution of CD4+ cell count is mainly driven by
ART use. The average CD4+ cell count for patients not
on ART remained below the cut-off for initiating ART
of 350 cells/mm3 during the first 12 weeks of TB treat-
ment. Therefore, a delayed assessment of the first CD4+
cell count in itself would probably not lead to missing
an opportunity to start ART based on the cut off of 350
cells/mm3. This finding is relevant in the Mozambican
setting where not all ART treatment facilities are capable
of performing CD4+ cell counts and prescription of
ART is prioritized. Health facilities sent blood samples
for CD4+ cell count to another laboratory daily or
weekly, depending on the distance between the sending
and receiving facilities.
This study showed a small increase in CD4+ cell count
during TB treatment in both patients on ART and
patients not on ART as has been described in non-
immune compromised TB patients [10,11]. In other
studies the CD4+ cell count in HIV-infected TB patients
not on ART did not increases [12,16]. It seems that the
immune response in HIV-infected TB patients not on
ART is variable.
This was a retrospective study based on routine data
and as such has several limitations. First, bias may have
occurred by not including patients who received HIV
treatment at another health facility. These patients may
have been treated differently or adherence may have
been different. This would have influenced treatment
outcome and CD4+ cell count. All health care facilities
in Mozambique follow the same national guidelines and
as such the chance of a difference in treatment strategy
is unlikely. Furthermore, the characteristics for patients
whose clinical record was identified were very similar
with those from patients without an HIV record
(Table 1).
Second, not all TB patients in this study had an HIV-
test or the result recorded in the TB register. Therefore,
not all HIV-infected TB patients were included. Given
the high testing rate of more than 80%, it is unlikely that
the non-availability of the HIV-test result would mark-
edly bias the results of the study.
Third, this study took place in three health facilities in
a single province of Mozambique. The results may be
different in other areas in Mozambique. However, we
believe that the situation in Manica does not differ much
from that in other provinces in the country at the time
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ART facilities are available. There is also more specialist
care available in the larger cities.
Fourth, despite a considerable amount of patients, the
number of available CD4+ cell counts per patient was
small, reflecting the indications in the national guidelines
as to when to perform this test. The use of the mixed
model allowed us to use all available data and was there-
fore the recommended methodology for our data set.
Fifth, about one third of the patients that used ART
during TB treatment started their ART before the start
of TB treatment and potentially had incident TB while
using ART. Emerging evidence shows that CD4+ cell
count response is smaller in these patients [17]. How-
ever, earlier evidence showed a similar CD4+ cell count
response in both patients with prevalent and those with
incident TB compared to patients on ART without TB
[18]. We cannot completely rule out a potential under-
estimation of the effect of TB treatment in our study.
However, the majority of patients did not have this inci-
dent TB and we are confident that our results are valid.
Despite these limitations, we consider the results rele-
vant and important because limited data are available on
CD4+ cell count response in cohorts of TB patients.
The presently used HIV treatment guidelines in
Mozambique are not yet in line with the WHO recom-
mendation to initiate ART in HIV-infected TB patients
as soon as possible after the start of TB treatment irre-
spective of the CD4+ cell count [8]. The present study
supports this recommendation as patients on ART had a
much better immune restoration than those not on
ART. However, like in Mozambique, these WHO guide-
lines have not yet been implemented everywhere.
Also, many countries with a high burden of HIV strug-
gle to maintain all HIV-infected patients on ART. Lack
of funding may lead to stock outs of antiretroviral drugs
at facility level [19]. Therefore countries may wish to
prioritize new initiations of ART to those most in need.
For HIV-infected TB patients, the CD4+ cell count pro-
vides a tool to prioritize. This study shows that obtaining
a sample for CD4+ cell count assessment in the first
12 weeks of TB treatment will be a reliable indicator for
the need to initiate ART, since this measurement is not
influenced by concurrent TB treatment. The opportunity
for identifying the HIV-infected TB patients most in
need of ART is unlikely to be missed.
Conclusion
In this study the higher CD4+ cell count level during TB
treatment in HIV-infected TB patients is due to ART
use, and not influenced by TB-treatment. Therefore,
these findings are a strong argument to implement the
recent WHO recommendation to start ART as soon as
possible in HIV-infected TB patients irrespective of theirCD4+ cell count. Should countries wish or need to
prioritize new ART initiations to those most in need, a
CD4+ cell count result obtained in the first 12 weeks of
TB treatment provides a good reflection of the immune
status at the start of TB treatment. This holds for
Mozambique and probably for other similar settings
as well.
A prospective study will provide better insight to the
question of the CD4+ cell count response during TB
treatment and the effect of TB treatment and ART on
this response.
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